Upcoming event
Masterclass on Non-muscle-invasive bladder cancer
Back

Tag: EAU22

EAU22 BCa highlights

Overall survival (OS) by circulating tumor DNA (ctDNA) status in patients with post-operative muscle-invasive urothelial carcinoma (MIUC) treated with atezolizumab (atezo): update from IMvigor010

Debate – NMIBC BCG refractory tumour – What are the systemic options in the pipeline?

Effect of robot-assisted radical cystectomy with intracorporeal urinary diversion vs. open radical cystectomy on 90-day morbidity and mortality among patients with bladder cancer: a randomised clinical trial

State-of-the-art lecture Molecular classification in bladder cancer to guide systemic treatment: ready from prime time?

State-of-the-art lecture Landscape of current trials with intravesical treatment in high risk BCG naïve NMIBC

[18F]-FDG PET/CT for bladder cancer staging and decision-making in patients with High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC)

Non-muscle invasive bladder cancer subtypes with differential response to intravesical bacillus Calmette-Guerin treatment

Overall survival (OS) by circulating tumor DNA (ctDNA) status in patients with post-operative muscle-invasive urothelial carcinoma (MIUC) treated with atezolizumab (atezo): update from IMvigor010

Effect of robot-assisted radical cystectomy with intracorporeal urinary diversion vs. open radical cystectomy on 90-day morbidity and mortality among patients with bladder cancer: a randomised clinical trial